Oh So Yeon, Jun Hyun Jung, Park Sung Jae, Park In Ki, Lim Ga Jin, Yu Yeonsil, Cho Sung-Ja, Song Aeran
1 Hematology and Medical Oncology, Department of Internal Medicine, Seoul Medical Center , Seoul, Republic of Korea.
J Palliat Med. 2014 Nov;17(11):1266-70. doi: 10.1089/jpm.2014.0082. Epub 2014 Jul 1.
Experts advise against parenteral nutrition (PN) for patients with advanced cancer at the end of life. But because many patients and families fear starvation, many physicians administer PN to patients with terminal cancer in Korea.
We designed this study to investigate the effect of PN on survival in patients with terminal cancer at the end of life.
We planned a randomized phase II study enrolling 116 patients randomized to receive either fluid or PN.
SETTING/SUBJECTS: Eligible patients are who could not tolerate enteral feeding and had short life expectancies (<3 months) due to progressive cancer. Patients with functioning bowels were excluded.
The primary end point was overall survival and the secondary end point was total administered calories.
We prospectively enrolled 31 consecutive patients and 16 patients were assigned to the PN group. The study ended early because many patients and families were extremely concerned about starvation. The baseline characteristics, including nutritional parameters, were not significantly different between the two groups. The mean administered calories was 374.7 (± 71.7) kcal/d for the fluid group and 1286.8 (± 108.3) kcal/d for the PN group (p<0.001). Median survival was 8 days (95% confidence interval [CI], 5.7-10.3 days) in the fluid group and 13 days (95% CI: 3.1-22.9 days) in the PN group, and this difference was not statistically significant (p = 0.982 by Log-rank test).
This study did not conclusively determine the role of PN for patients with advanced cancer, however, PN support failed to significantly prolong survival in these patients compared to similar patients receiving only fluid.
专家建议不要为晚期癌症临终患者提供肠外营养(PN)。但由于许多患者和家属担心患者会饥饿,韩国许多医生仍会为晚期癌症患者实施PN。
我们开展本研究以调查PN对晚期癌症临终患者生存的影响。
我们计划进行一项随机II期研究,招募116例患者随机接受补液或PN。
设置/研究对象:符合条件的患者为因癌症进展而无法耐受肠内喂养且预期寿命较短(<3个月)的患者。肠道功能正常的患者被排除。
主要终点为总生存期,次要终点为总摄入热量。
我们前瞻性纳入了31例连续患者,16例患者被分配到PN组。由于许多患者和家属极度担心饥饿问题,研究提前结束。两组之间的基线特征,包括营养参数,无显著差异。补液组平均摄入热量为374.7(±71.7)kcal/d,PN组为1286.8(±108.3)kcal/d(p<0.001)。补液组中位生存期为8天(95%置信区间[CI],5.7 - 10.3天),PN组为13天(95%CI:3.1 - 22.9天),差异无统计学意义(对数秩检验p = 0.982)。
本研究未能最终确定PN对晚期癌症患者的作用,然而,与仅接受补液的类似患者相比,PN支持未能显著延长这些患者的生存期。